Anzahl der Publikationen: 3
Zeitschriftenartikel
Zimmermann, Heiner; Babel, Nina; Dierickx, Daan; Morschhauser, Franck; Mollee, Peter; Zaucha, Jan M.; Dreyling, Martin H.; Dührsen, Ulrich; Reinke, Petra; Verhöf, Gregor; Subklewe, Marion; Hüttmann, Andreas; Tousseyn, Thomas; Bachy, Emmanuel; Hauser, Ingeborg A.; Tarella, Corrado; Van den Neste, Eric; Gheysens, Olivier; Anagnostopoulos, Ioannis; Leblond, Veronique; Riess, Hanno; Choquet, Sylvain und Trappe, Ralf U.
(2018):
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
In: Transplantation, Bd. 102, Nr. 11: S. 1914-1923
[PDF, 0B]
Borchmann, Peter; Goergen, Helen; Kobe, Carsten; Lohri, Andreas; Greil, Richard; Eichenauer, Dennis A.; Zijlstra, Josee M.; Markova, Jana; Meissner, Julia; Feuring-Buske, Michaela; Hüttmann, Andreas; Dierlamm, Judith; Sökler, Martin; Beck, Hans-Joachim; Willenbacher, Wolfgang; Ludwig, Wolf-Dieter; Pabst, Thomas; Topp, Max S.; Hitz, Felicitas; Bentz, Martin; Keller, Ulrich Bernd; Kuhnhardt, Dagmar; Ostermann, Helmut; Schmitz, Norbert; Hertenstein, Bernd; Aulitzky, Walter; Maschmeyer, Georg; Vieler, Tom; Eich, Hans; Baues, Christian; Stein, Harald; Fuchs, Michael; Kuhnert, Georg; Diehl, Volker; Dietlein, Markus und Engert, Andreas
(2017):
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
In: Lancet, Bd. 390, Nr. 10114: S. 2790-2802
Trappe, Ralf U.; Dierickx, Daan; Zimmermann, Heiner; Morschhauser, Franck; Mollee, Peter; Zaucha, Jan M.; Dreyling, Martin H.; Dührsen, Ulrich; Reinke, Petra; Verhoef, Gregor; Subklewe, Marion; Hüttmann, Andreas; Tousseyn, Thomas; Salles, Gilles; Kliem, Volker; Hauser, Ingeborg A.; Tarella, Corrado; Neste, Eric van den; Gheysens, Olivier; Anagnostopoulos, Ioannis; Leblond, Veronique; Riess, Hanno und Choquet, Sylvain
(2017):
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
In: Journal of Clinical Oncology, Bd. 35, Nr. 5:
536-+
Diese Liste wurde am
Sat Dec 21 20:15:33 2024 CET
erstellt.